Title : CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants.

Pub. Date : 2020 Aug

PMID : 32065000






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The treatment with amiodarone, a CYP3A4 inhibitor, influenced neither the metabolic ratios nor the ADP-induced platelet reactivity.The CYP3A4 and CYP2C19 metabolic activity is associated with ADP-induced platelet reactivity in prasugrel-treated, but not ticagrelor-treated patients with STEMI. ticagrelor cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 The treatment with amiodarone, a CYP3A4 inhibitor, influenced neither the metabolic ratios nor the ADP-induced platelet reactivity.The CYP3A4 and CYP2C19 metabolic activity is associated with ADP-induced platelet reactivity in prasugrel-treated, but not ticagrelor-treated patients with STEMI. ticagrelor cytochrome P450 family 2 subfamily C member 19 Homo sapiens